Consequently, ROCK2 inhibitors have potential therapeutic value for glaucoma, as well as other diseases such as erectile dysfunction, cardiovascular disease, central nervous system disease, fibrotic disease, inflammation, and diabetes [8,9,10,11,12]. This evidence concerns the gene ROCK2 and glaucoma.